STOCK TITAN

Numinus Wellness Inc. - NUMIF STOCK NEWS

Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.

About Numinus Wellness Inc. (NUMIF)

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) is a pioneering mental health care company dedicated to advancing traditional and innovative behavioral health treatments, with a particular emphasis on safe, evidence-based psychedelic-assisted therapies. Headquartered in Vancouver, British Columbia, Numinus integrates clinical research, therapeutic services, and practitioner training to address complex mental health challenges such as depression, anxiety, trauma, pain, and substance use disorders. The company’s mission is to transform mental health care by focusing on healing rather than merely managing symptoms, thereby fostering a healthier society.

Core Business Areas

  • Clinical Research: Through its Cedar Clinical Research (CCR) division, Numinus is at the forefront of psychedelic clinical trials, supporting drug developers in exploring the efficacy and safety of novel therapies for conditions like Major Depressive Disorder (MDD). CCR has participated in multiple high-profile trials, showcasing its expertise in advancing groundbreaking treatments.
  • Therapeutic Services: Numinus operates a network of wellness clinics in the United States, providing evidence-based therapies, including ketamine and esketamine treatments. These services are supported by a robust call center and expertise in insurance reimbursement, ensuring accessible and high-quality care for patients.
  • Practitioner Training: The company offers comprehensive training programs for health care providers, equipping them with the skills needed to deliver psychedelic-assisted therapies. These programs are accredited by major regulatory bodies in Canada and the U.S., enhancing the professionalization of this emerging field.

Market Position and Differentiation

Numinus is strategically positioned within the rapidly evolving mental health care and psychedelic-assisted therapy sectors. By integrating clinical research, therapeutic services, and training under one umbrella, the company offers a unique value proposition that sets it apart from competitors. Its partnerships with leading organizations and its role in pivotal clinical trials further underscore its commitment to innovation and evidence-based practices.

Operational Focus and Recent Developments

Numinus has recently undertaken significant restructuring efforts to streamline its operations and focus on its core business areas. This includes transitioning out of Canadian clinical operations and forming strategic partnerships to optimize resource allocation. The company remains committed to achieving profitability through an asset-light model while continuing to expand its impact in the U.S. market.

Commitment to Expertise and Trust

Numinus is led by a team of seasoned professionals with deep expertise in mental health care, clinical research, and corporate strategy. Its adherence to rigorous scientific standards and regulatory compliance ensures the safety and efficacy of its treatments. By fostering transparency and collaboration, Numinus builds trust among patients, practitioners, and stakeholders alike.

Conclusion

Numinus Wellness Inc. is not just a company; it is a catalyst for change in the mental health care industry. By championing innovative therapies and integrating them into mainstream clinical practice, Numinus is paving the way for a future where mental health challenges are addressed with compassion, science, and efficacy.

Rhea-AI Summary

Numinus Wellness Inc. announces a strategic plan to focus on U.S. operations for higher growth and profitability. The company is enhancing its wellness clinics and clinical research facilities, launching a membership program for healthcare professionals in psychedelic-assisted therapies, and collaborating with Field Trip Health. Numinus also entered into an agreement with Field Trip Health to transition Canadian clinic operations, aiming to optimize therapy and training expertise while maximizing shareholder returns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.43%
Tags
none
-
Rhea-AI Summary
Numinus Wellness Inc. announces Cedar Clinical Research as a site for Cybin's Phase 3 trial of CYB003 for Major Depressive Disorder. In Phase 2, 75% of patients achieved remission from depression symptoms. The FDA granted CYB003 breakthrough therapy designation. Phase 3 enrollment starts mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.08%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. provides a corporate update focusing on streamlining operations, maximizing shareholder returns, expanding Psychedelic Assisted Therapy training, and exploring opportunities to redefine, divest, or discontinue Canadian clinical operations. The company sharpens its focus on growth opportunities in the U.S. while maintaining support for Canadian organizations and healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
none
Rhea-AI Summary
Numinus Wellness Inc. reported Q2 Fiscal 2024 results with a cash position of $6.6 million, a gross profit of $0.5 million, and revenue of $5.0 million. The company doubled enrolment in training programs, managed 15 clinical trials, and provided 17,661 client appointments. Numinus submitted a Clinical Trial Application to Health Canada for MDMA-assisted psychotherapy. Despite revenue and gross margin declines, the company focused on profitability and cost containment measures. Operational highlights include revenue decline in wellness clinics, clinical research revenues, and clinical training program success. Corporate updates included key appointments and retirements. Numinus ended the quarter with $6.6 million in cash and a positive outlook for growth in the psychedelic sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. to release financial results for Q2 2024 on April 15, 2024. The company focuses on psychedelic-assisted therapies for mental health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences earnings
-
Rhea-AI Summary
Numinus Wellness Inc. submits a Clinical Trial Application to Health Canada for a group model in MDMA-assisted psychotherapy, focusing on practitioner training and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
Rhea-AI Summary
Numinus Wellness Inc. announces the new date for its Annual General Meeting, along with the appointment of directors and an interim Chief Financial Officer. The company is focused on mental health care and innovative behavioral health treatments, with a strong emphasis on evidence-based therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
Rhea-AI Summary
Numinus Wellness Inc. congratulates Mind Medicine on positive data from Phase 2b clinical trial of MM120 for GAD, showing significant improvement in anxiety treatment. FDA designates MM120 as a breakthrough therapy for GAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. announced its Q1 2024 financial results, reporting a gross profit of $2.1 million, a 18.8% increase over Q4 2023, and a revenue decline of 3.0%. The company reduced operating expenditures by 19.9% and achieved a cash position of $4.7 million. Numinus managed 22 clinical trials and provided 19,961 client appointments in its wellness clinics. The company's focus on cost containment efforts resulted in a monthly cash burn rate of less than $1 million. Revenue declined due to a contraction in scheduled appointments at wellness clinics, but gross margin increased by 660 basis points. The company continues to focus on profitability and sustainability, with a total cash balance of $4.7 million and working capital of $4.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.39%
Tags
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) to release Q1 2024 financial results on January 15, 2024, with a focus on psychedelic-assisted therapies. Investors and analysts can participate in the conference call and webcast to review the Company's performance and recent initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.95%
Tags
conferences earnings

FAQ

What is the current stock price of Numinus Wellness (NUMIF)?

The current stock price of Numinus Wellness (NUMIF) is $0.0321 as of March 3, 2025.

What is the market cap of Numinus Wellness (NUMIF)?

The market cap of Numinus Wellness (NUMIF) is approximately 9.8M.

What does Numinus Wellness Inc. do?

Numinus Wellness Inc. specializes in mental health care, focusing on safe, evidence-based psychedelic-assisted therapies, clinical research, and practitioner training.

How does Numinus generate revenue?

Numinus generates revenue through therapeutic services at its wellness clinics, clinical research partnerships, and practitioner training programs.

What makes Numinus unique in the mental health care industry?

Numinus integrates clinical research, therapeutic services, and training into a unified model, offering a comprehensive approach to advancing mental health care and psychedelic-assisted therapies.

What conditions does Numinus address?

Numinus focuses on treating conditions such as depression, anxiety, trauma, pain, and substance use disorders through innovative and evidence-based therapies.

Where does Numinus operate its clinics?

Numinus operates a network of wellness clinics in the United States, providing advanced mental health care services.

What is Cedar Clinical Research?

Cedar Clinical Research is Numinus's clinical research division, which conducts trials to evaluate the safety and efficacy of psychedelic-assisted therapies for mental health conditions.

Does Numinus offer training for practitioners?

Yes, Numinus provides accredited training programs for practitioners to deliver psychedelic-assisted therapies, including ketamine, MDMA, and psilocybin treatments.

Is Numinus focused on profitability?

Yes, Numinus has implemented cost optimization strategies and shifted to an asset-light model to achieve profitability while maintaining its focus on core operations.

What partnerships has Numinus formed?

Numinus collaborates with leading organizations in the psychedelic therapy space and has been selected as a trial site for pivotal clinical studies, such as Cybin's Phase 3 trial for CYB003.

What is Numinus's mission?

Numinus's mission is to transform mental health care by focusing on healing rather than managing symptoms, integrating innovative therapies into mainstream clinical practice.
Numinus Wellness Inc.

OTC:NUMIF

NUMIF Rankings

NUMIF Stock Data

9.81M
313.99M
3.85%
2.67%
Medical Care Facilities
Healthcare
Link
Canada
Vancouver